BioXcel Therapeutics, Inc. reported on August 27, 2025, that its SERENITY At-Home Phase 3 trial for BXCL501 successfully met its primary endpoint, evaluating treatment for agitation in patients with bipolar disorders or schizophrenia, with 246 patients participating and 81% completing the trial. The data suggests a significant market need, estimating 57 to 77 million agitation episodes annually in the U.S.